AxonDAO Leaves GPU Marketplaces Behind
The decentralized science startup says it will run regulated AI workloads on Oracle Cloud Infrastructure
AxonDAO LLC this week has selected Oracle Cloud Infrastructure (OCI) to build and scale secure GPU infrastructure for artificial intelligence and life sciences workloads. The company stated that the platform will deliver “secure, sovereign, and compliant GPU infrastructure suitable for regulated artificial intelligence, healthcare, and life sciences applications.”
“Trust is becoming the defining requirement for advanced AI and scientific computing,” said Chris Crecelius, founder and chief executive officer of AxonDAO. AxonDAO also said it is transitioning from monetizing GPUs through secondary marketplaces to offering “direct, infrastructure enforced compute services designed for sensitive, human origin data.”
The deployment will run in Oracle Cloud regions located in the United States. The company said this reduces exposure to cross-border data replication risks. It also stated that the environment uses customer-managed encryption key capabilities available within OCI and is configured to prevent the creation of unencrypted data.
Chris Gandolfo, Executive Vice President of Oracle Cloud Infrastructure and AI, said, “Customers who run demanding AI and scientific workloads with sensitive data need infrastructure that can deliver both extreme performance with enterprise-grade security. OCI is purpose-built for these workloads, enabling customers like AxonDAO to build scalable, secure environments while addressing compliance requirements.”
AxonDAO said its OCI deployment enables direct control over firewall rules, network access, and traffic monitoring to meet operational and regulatory expectations.
A Change in Revenue Strategy
AxonDAO operates as a decentralized science (DeSci) platform. According to its whitepaper, the company enables individuals to control and monetize their health data through blockchain-based governance and consent mechanisms.
The whitepaper states that the platform combines biometric data collection, cryptographic consent controls, and AI analytics. It also describes the use of GPU-accelerated AI to process biomedical and behavioral datasets.
AxonDAO uses a utility token, AXGT, to support governance participation, proposal submission, and ecosystem incentives. Token holders participate in decentralized autonomous organization voting related to research funding and platform development.
In 2024, AxonDAO announced A+Voice, a biometric voice initiative that uses AI-driven analysis of vocal data to identify patterns associated with health conditions.
AI training and inference workloads in biomedical research require high-performance GPU infrastructure. AxonDAO’s February 2026 announcement states that infrastructure readiness is a prerequisite for expanding its broader data and compute platform for user-owned scientific data.
The company did not disclose financial terms of the Oracle agreement, deployment timelines, hardware specifications, or customer names.
Enterprise Guardrails for Scientific AI
AI systems in healthcare and life sciences frequently process personally identifiable information and protected health data. In the United States, regulatory frameworks such as the Health Insurance Portability and Accountability Act (HIPAA) establish requirements for data protection, access controls, and auditability.
Cloud infrastructure providers serving regulated industries typically offer region-specific deployment options, encryption at rest and in transit, identity and access management controls, and network isolation capabilities.
Oracle Cloud Infrastructure offers customer-managed key services through its key management system and supports region-restricted deployments.
AxonDAO stated that its configuration within OCI enforces encryption policies and maintains U.S.-based regional deployment. The company also stated that it retains direct control over firewall rules and network traffic monitoring within its OCI environment.
AxonDAO said the selection of OCI supports its plan to build a secure AI and scientific compute platform designed for enterprise, healthcare, and research institutions.
The announcement did not include performance benchmarks, revenue projections, or named institutional partners.